[Cholangiographic agents in chronic liver diseases: Can toxic liver cell damages be caused by jodoxamid?].
Jodoxamid, a new intravenous radiocontrast agent, did not increase serum enzymes and serum bilirubin in 40 patients with active chronic liver diseases diagnosed by laparoscopy and biopsy. The most necessary examination of the biliary tract in patients with liver diseases is obviously unobjectionable using this radiocontrast agent as well by injection as by infusion.
D000328:Adult; D000368:Aged; D001663:Bilirubin / Q000097:blood; D002758:Cholangiography; D003287:Contrast Media; D004798:Enzymes / Q000097:blood; D005260:Female; D006801:Humans; D007463:Iodobenzoates / Q000009:adverse effects*; D008107:Liver Diseases / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D014283:Triiodobenzoic Acids / Q000009:adverse effects*
D003287:Contrast Media; D004798:Enzymes; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D001663:Bilirubin
Gallenkontrastmittel bei chronischen Leberkrankheiten.